The Place of Radiopharmaceuticals in an Evolving Treatment Landscape: Addressing Perceptions With Clinical Evidence to Optimise Outcomes in Men With Metastatic Prostate Cancer

Visit https://www.peervoice.com/ZMJ860 to view the entire programme with slides. After completing “The Place of Radiopharmaceuticals in an Evolving Treatment Landscape: Addressing Perceptions With Clinical Evidence to Optimise Outcomes in Men With Metastatic Prostate Cancer”, participants will be able to: Describe the benefits and limitations of radium-223 within the current standard of care for metastatic prostate cancer (mPC) and within the context of emerging radiopharmaceuticals; Explain the rationale for radiopharmaceuticals as a key component of active lines of therapy for mPC, based on clinical evidence; Summarise the limitations of prostate-specific antigen (PSA) as a biomarker for treatment response in mPC; Explain why bone health is an important consideration in all men with mPC and propose strategies for preserving bone health; Identify the most appropriate place in therapy for radium-223 and radioligand therapy, based on patient and disease characteristics